Latest news with #PharmaMar
Yahoo
8 hours ago
- Business
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 days ago
- Business
- Yahoo
PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for lurbinectedin Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet PharmaMar to host a webcast with Key Opinion Leaders on Thursday, June 12th, to review lurbinectedin data MADRID, June 3, 2025 /PRNewswire/ -- PharmaMar (MSE: PHM) has announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone. IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC and supports maintenance therapy with lurbinectedin plus atezolizumab as a new standard of care for patients. The data were presented today in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published simultaneously in The Lancet. Data from the trial served as the basis for the supplemental New Drug Application (sNDA) submission to the FDA by Jazz Pharmaceuticals, as well as for the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) by PharmaMar. Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive lurbinectedin plus atezolizumab or atezolizumab alone. From the point of randomization, the median PFS was 5.4 months for the lurbinectedin plus atezolizumab combination versus 2.1 months for atezolizumab alone (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001), and median OS was 13.2 months versus 10.6 months (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). The combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone. The lurbinectedin plus atezolizumab combination had no new or unexpected safety signals. "Small cell lung cancer is an aggressive and devastating disease; at the time of diagnosis, the large majority of patients have already progressed to extensive-stage disease and only one out of five survive longer than two years," said Luis Paz-Ares, M.D., Ph.D., head of medical oncology at the Hospital Universitario 12 de Octubre in Madrid, Spain, and the IMforte trial principal investigator. "The IMforte results are very encouraging showing a potentially practice-changing option that could improve survival for patients with a very high unmet need." "Upon approval, patients will have access to lurbinectedin earlier in the treatment paradigm, where there's potential to increase duration of response in a broader patient population, delaying disease progression and extending survival," said Javier Jiménez Jiménez, Chief Medical Officer of PharmaMar. Each year, approximately 63,000 to 72,000 new cases of small cell lung cancer (SCLC) are reported in Europe. Most of these patients are diagnosed with extensive stage disease, which is aggressive and often difficult to treat, with poor prognosis.[i],[ii],[iii] Legal warning This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Phase 3 IMforte Trial Results These primary results are from the global Phase 3 IMforte trial, which evaluated lurbinectedin plus atezolizumab as a first-line maintenance therapy in patients with ES-SCLC. 483 patients were randomized after completion of 4 cycles of induction therapy with atezolizumab plus carboplatin and etoposide. From the point of randomization, the median OS for the lurbinectedin plus atezolizumab regimen was 13.2 months versus 10.6 months for atezolizumab alone (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). From the point of randomization, the median PFS by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001). Treatment duration for patients in the lurbinectedin plus atezolizumab arm was twice as long as the atezolizumab arm, with a median maintenance treatment duration of 4.2 months versus 2.1 months, respectively. The lurbinectedin plus atezolizumab combination as maintenance therapy was generally well tolerated with no new safety signals identified. In the lurbinectedin plus atezolizumab and atezolizumab arms, respectively, treatment-related adverse events (TRAEs) occurred in 83.5% versus 40.0% of patients, with Grade 3-4 TRAEs in 25.6% versus 5.8% and Grade 5 TRAEs in 0.8% (two patients with sepsis and febrile neutropenia) versus 0.4% (one patient with sepsis). AEs led to treatment discontinuation in 6.2% of patients in the lurbinectedin plus atezolizumab arm and 3.3% of patients in the atezolizumab arm. PharmaMar will host a Key Opinion Leader webcast on June 12nd to review lurbinectedin data. The webcast will include a discussion panel of Dr. Martin Wermke from TU Dresden and Dr. Nicolas Girard from Institut Curie. The webcast may be accessed from the Investors section at About the IMforte Phase 3 Trial IMforte (NCT05091567) is an ongoing Phase 3, randomized, multicenter maintenance trial evaluating the efficacy, safety and pharmacokinetic of lurbinectedin plus atezolizumab, compared with standard-of-care first-line maintenance with atezolizumab alone, in adults (≥18 years) with ES-SCLC, following induction therapy with carboplatin, etoposide and atezolizumab. The primary endpoints for this study are OS and IRF-assessed PFS in the maintenance phase. The trial consists of two phases: an induction phase and a maintenance phase. Participants were required to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 after the induction phase of four cycles of carboplatin, etoposide, and atezolizumab to be considered for eligibility screening for the maintenance phase. Eligible participants were randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase. The trial is sponsored by Roche and co-funded by Jazz Pharmaceuticals. Additional information about the trial, including eligibility criteria and a list of clinical trial sites, can be found at: ( Identifier: NCT05091567). About PharmaMar PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at About Zepzelca® Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets. [i] Cancer today. (s. f.). Alvarado-Lunda G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? – A review. Transl Lung Cancer Res. 2016;5(1):26-38.[iii] SEER Explorer Lung and Bronchus Cancer, Recent Trends in SEER Incidence Rates, 2000-2016, by Age, Updated June 27, 2024. Accessed October 10, 2024. Photo - - View original content to download multimedia: Sign in to access your portfolio
Zawya
30-05-2025
- Business
- Zawya
Jordan: ASEZA approves new agreements to boost research, investment, culture, sports in Aqaba
AMMAN — The Board of Commissioners of the Aqaba Special Economic Zone Authority (ASEZA) on Thursday decided to approve an "initial" agreement with the Spanish PharmaMar Company for the Access and Benefit-Sharing (ABD) of scientific research. This decision comes within the authority's vision related to the pillar of sustainable growth, investment encouragement and the development of scientific research, for the purposes of exploration, collection and examination of marine organisms from Jordanian territorial waters. The aim of the decision is to launch biological research and drug discovery, provided that the procedures for obtaining the necessary approvals under the protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilisation to the Convention on Biological Diversity (CBD) No. (20) of 2021 are completed. In regards to the pillar of institutional development and investment promotion, ASEZA decided to approve the amended bylaw for the "temporary" admission of vehicles for the ASEZA, which will provide a number of incentives to investors and companies. This decision comes within the authority's vision to promote investment, enhance Aqaba's position as a "regional" logistics hub, and encourage companies to register and benefit from the investment incentives offered by ASEZA to investors and investment companies. In regards to the pillar of leadership, innovation and community development, ASEZA decided to agree to contribute to supporting a cultural association to organise and establish a forum for art and culture in Aqaba, with the participation of artists from Arab countries. This decision comes within the authority's vision to promote and develop a culture of entrepreneurship and innovation in the culture and arts sector, as this forum seeks to promote cultural tourism within the authority's vision to make it an international centre for holding artistic and cultural events. The board also decided to approve the contribution in supporting a sports club in order to participate in the championships of Jordan Football Association in the 2025/2026 football season, through the participation of multiple age groups. The football club aims to encourage sports tourism and support young people in various sports, which contribute to activating the sports and commercial movement in Aqaba. © Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (
Yahoo
26-05-2025
- Business
- Yahoo
European Growth Companies With High Insider Ownership In May 2025
In recent weeks, European markets have faced downward pressure as the pan-European STOXX Europe 600 Index ended lower, influenced by proposed U.S. tariffs on EU goods and a contraction in eurozone business activity. Amid this backdrop of economic uncertainty and revised growth forecasts, identifying growth companies with high insider ownership can be particularly appealing to investors seeking stability and alignment with management interests. Name Insider Ownership Earnings Growth KebNi (OM:KEBNI B) 38.3% 67% Yubico (OM:YUBICO) 36.2% 30.4% Vow (OB:VOW) 13.1% 81% Pharma Mar (BME:PHM) 11.8% 43.1% Bonesupport Holding (OM:BONEX) 10.4% 56.1% Bergen Carbon Solutions (OB:BCS) 12% 63.2% CD Projekt (WSE:CDR) 29.7% 37.4% Lokotech Group (OB:LOKO) 14.5% 58.1% Xbrane Biopharma (OM:XBRANE) 21.8% 56.8% Elliptic Laboratories (OB:ELABS) 25.8% 79% Click here to see the full list of 211 stocks from our Fast Growing European Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★★★ Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on researching, developing, producing, and commercializing bio-active principles for oncology across various international markets with a market cap of €1.48 billion. Operations: The company generates revenue primarily from its oncology segment, amounting to €178.70 million. Insider Ownership: 11.8% Pharma Mar, a company with significant insider ownership, is experiencing strong growth prospects despite recent financial setbacks. Although it reported a net loss of €3.95 million in Q1 2025, its revenue increased to €38.86 million from the previous year. Analysts forecast robust annual earnings growth of 43.1%, significantly outpacing the Spanish market average of 4.9%. The company's shares are trading well below estimated fair value, suggesting potential for future appreciation if forecasts hold true. Click to explore a detailed breakdown of our findings in Pharma Mar's earnings growth report. In light of our recent valuation report, it seems possible that Pharma Mar is trading beyond its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: VusionGroup S.A. provides digitalization solutions for commerce across Europe, Asia, and North America with a market cap of €3.49 billion. Operations: The company generates revenue of €954.71 million from installing and maintaining electronic shelf labels. Insider Ownership: 13.4% VusionGroup exhibits strong growth potential with high insider ownership, despite recent share price volatility. Analysts project a 67.39% annual earnings growth rate over the next three years, outpacing the French market's revenue growth forecast of 5%. A recent private placement reduced BOE Smart Retail's stake to approximately 25%, enhancing VusionGroup's free float to 47%. The company declared an annual dividend of €0.60 per share, reflecting confidence in its financial outlook. Click here to discover the nuances of VusionGroup with our detailed analytical future growth report. Our valuation report unveils the possibility VusionGroup's shares may be trading at a premium. Simply Wall St Growth Rating: ★★★★★★ Overview: CTT Systems AB (publ) specializes in providing humidity control systems for aircraft across Sweden, Denmark, France, the United States, and internationally, with a market cap of SEK2.57 billion. Operations: The company generates revenue from its Aerospace & Defense segment, amounting to SEK278 million. Insider Ownership: 17.5% CTT Systems demonstrates robust growth potential, with earnings projected to grow significantly at 34.23% annually, surpassing the Swedish market's 15.9%. Despite a recent decline in Q1 sales and net income compared to last year, revenue is forecasted to increase by 22.5% per year, outpacing the local market's growth rate of 4.2%. The company's stock trades at a substantial discount to its estimated fair value, although its dividend yield of 2.6% remains inadequately covered by earnings or free cash flows. Delve into the full analysis future growth report here for a deeper understanding of CTT Systems. According our valuation report, there's an indication that CTT Systems' share price might be on the expensive side. Take a closer look at our Fast Growing European Companies With High Insider Ownership list of 211 companies by clicking here. Ready To Venture Into Other Investment Styles? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include BME:PHM ENXTPA:VU and OM:CTT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
26-05-2025
- Business
- Yahoo
European Growth Companies With High Insider Ownership In May 2025
In recent weeks, European markets have faced downward pressure as the pan-European STOXX Europe 600 Index ended lower, influenced by proposed U.S. tariffs on EU goods and a contraction in eurozone business activity. Amid this backdrop of economic uncertainty and revised growth forecasts, identifying growth companies with high insider ownership can be particularly appealing to investors seeking stability and alignment with management interests. Name Insider Ownership Earnings Growth KebNi (OM:KEBNI B) 38.3% 67% Yubico (OM:YUBICO) 36.2% 30.4% Vow (OB:VOW) 13.1% 81% Pharma Mar (BME:PHM) 11.8% 43.1% Bonesupport Holding (OM:BONEX) 10.4% 56.1% Bergen Carbon Solutions (OB:BCS) 12% 63.2% CD Projekt (WSE:CDR) 29.7% 37.4% Lokotech Group (OB:LOKO) 14.5% 58.1% Xbrane Biopharma (OM:XBRANE) 21.8% 56.8% Elliptic Laboratories (OB:ELABS) 25.8% 79% Click here to see the full list of 211 stocks from our Fast Growing European Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★★★ Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on researching, developing, producing, and commercializing bio-active principles for oncology across various international markets with a market cap of €1.48 billion. Operations: The company generates revenue primarily from its oncology segment, amounting to €178.70 million. Insider Ownership: 11.8% Pharma Mar, a company with significant insider ownership, is experiencing strong growth prospects despite recent financial setbacks. Although it reported a net loss of €3.95 million in Q1 2025, its revenue increased to €38.86 million from the previous year. Analysts forecast robust annual earnings growth of 43.1%, significantly outpacing the Spanish market average of 4.9%. The company's shares are trading well below estimated fair value, suggesting potential for future appreciation if forecasts hold true. Click to explore a detailed breakdown of our findings in Pharma Mar's earnings growth report. In light of our recent valuation report, it seems possible that Pharma Mar is trading beyond its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: VusionGroup S.A. provides digitalization solutions for commerce across Europe, Asia, and North America with a market cap of €3.49 billion. Operations: The company generates revenue of €954.71 million from installing and maintaining electronic shelf labels. Insider Ownership: 13.4% VusionGroup exhibits strong growth potential with high insider ownership, despite recent share price volatility. Analysts project a 67.39% annual earnings growth rate over the next three years, outpacing the French market's revenue growth forecast of 5%. A recent private placement reduced BOE Smart Retail's stake to approximately 25%, enhancing VusionGroup's free float to 47%. The company declared an annual dividend of €0.60 per share, reflecting confidence in its financial outlook. Click here to discover the nuances of VusionGroup with our detailed analytical future growth report. Our valuation report unveils the possibility VusionGroup's shares may be trading at a premium. Simply Wall St Growth Rating: ★★★★★★ Overview: CTT Systems AB (publ) specializes in providing humidity control systems for aircraft across Sweden, Denmark, France, the United States, and internationally, with a market cap of SEK2.57 billion. Operations: The company generates revenue from its Aerospace & Defense segment, amounting to SEK278 million. Insider Ownership: 17.5% CTT Systems demonstrates robust growth potential, with earnings projected to grow significantly at 34.23% annually, surpassing the Swedish market's 15.9%. Despite a recent decline in Q1 sales and net income compared to last year, revenue is forecasted to increase by 22.5% per year, outpacing the local market's growth rate of 4.2%. The company's stock trades at a substantial discount to its estimated fair value, although its dividend yield of 2.6% remains inadequately covered by earnings or free cash flows. Delve into the full analysis future growth report here for a deeper understanding of CTT Systems. According our valuation report, there's an indication that CTT Systems' share price might be on the expensive side. Take a closer look at our Fast Growing European Companies With High Insider Ownership list of 211 companies by clicking here. Ready To Venture Into Other Investment Styles? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include BME:PHM ENXTPA:VU and OM:CTT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
